A number of other research firms have also commented on QTNT. Jefferies Financial Group increased their price target on Quotient from $11.00 to $13.50 and gave the company a buy rating in a research report on Tuesday, March 5th. ValuEngine raised Quotient from a buy rating to a strong-buy rating in a research report on Saturday, February 2nd. Finally, Zacks Investment Research upgraded Quotient from a sell rating to a hold rating in a research note on Wednesday, April 10th.
QTNT traded down $0.40 during trading on Tuesday, hitting $9.67. The company’s stock had a trading volume of 456,592 shares, compared to its average volume of 370,517. Quotient has a twelve month low of $5.52 and a twelve month high of $11.15. The company has a debt-to-equity ratio of 4.95, a quick ratio of 6.05 and a current ratio of 6.87. The firm has a market cap of $628.85 million, a PE ratio of -5.04 and a beta of 1.25.
In other news, President Edward Farrell sold 22,500 shares of the stock in a transaction on Wednesday, May 8th. The stock was sold at an average price of $8.67, for a total transaction of $195,075.00. Following the completion of the transaction, the president now owns 2,133 shares in the company, valued at approximately $18,493.11. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, President Jeremy Stackawitz sold 21,495 shares of the firm’s stock in a transaction dated Wednesday, May 29th. The stock was sold at an average price of $9.93, for a total value of $213,445.35. Following the completion of the transaction, the president now owns 131,939 shares of the company’s stock, valued at approximately $1,310,154.27. The disclosure for this sale can be found here. 17.40% of the stock is owned by corporate insiders.
Hedge funds and other institutional investors have recently modified their holdings of the business. Highbridge Capital Management LLC boosted its stake in Quotient by 47.5% in the 4th quarter. Highbridge Capital Management LLC now owns 3,003,433 shares of the company’s stock worth $18,382,000 after purchasing an additional 967,096 shares during the period. Bellevue Group AG raised its holdings in shares of Quotient by 15.5% in the 4th quarter. Bellevue Group AG now owns 833,619 shares of the company’s stock valued at $5,102,000 after acquiring an additional 111,761 shares in the last quarter. Casdin Capital LLC purchased a new stake in shares of Quotient in the 4th quarter valued at about $1,989,000. Monashee Investment Management LLC purchased a new stake in shares of Quotient in the 4th quarter valued at about $1,530,000. Finally, Quantum Capital Management raised its holdings in shares of Quotient by 42.3% in the 4th quarter. Quantum Capital Management now owns 385,558 shares of the company’s stock valued at $2,360,000 after acquiring an additional 114,597 shares in the last quarter. Institutional investors and hedge funds own 65.82% of the company’s stock.
Quotient Limited, a commercial-stage diagnostics company, develops, manufactures, and commercializes conventional reagent products used for blood grouping in the transfusion diagnostics market worldwide. The company is developing MosaiQ, a proprietary technology platform, which provides tests for blood grouping and serological disease screening.
Featured Story: How does new data get added to a blockchain?
Receive News & Ratings for Quotient Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quotient and related companies with MarketBeat.com's FREE daily email newsletter.